Fellows' Journal Club

Schedule

Noon-1:00 PM (alternates with Tumor Board)
11th Floor Mid-Campus Center, North Conference Room (in person)
Zoom (virtual)

2021-2022 Academic Year

Date Speaker Title Download
Jan 13, 2022 Jing Xi Breast Cancer
Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study
➤ PubMed
Whitney Hensing Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR1, HER22, Node-Positive, High-Risk, Early Breast Cancer (monarchE) ➤ PubMed
- - Trastuzumab Deruxtecan (T-DXd) Vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) With HER2+ Metastatic Breast Cancer (MBC): Results of the Randomized Phase III DESTINY-Breast03 Study ➤ .pdf
Mar 31, 2022 Raya Saba Cutaneous/Soft Tissue Cancers
Overall Survival Benefit With Tebentafusp in Metastatic Uveal Melanoma
➤ PubMed
Giordano Cittolin-Santos Relatlimab and Nivolumab Versus Nivolumab in Untreated Advanced Melanoma ➤ PubMed
Apr 13, 2022 Jared Cohen Lung Cancer
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
➤ PubMed
Alice Zhou Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial ➤ PubMed
Apr 28, 2022 Michael Kramer Gastrointestinal Cancer
Temozolomide Followed by CombinationWith Low-Dose Ipilimumab and Nivolumabin Patients With Microsatellite-Stable,O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: TheMAYA Trial
➤ PubMed
Michael Iglesia Trastuzumab Deruxtecan (DS-8201) in Patients With HER2-Expressing Metastatic Colorectal Cancer (DESTINY-CRC01): A Multicentre, Open-Label, Phase 2 Trial ➤ PubMed
May 12, 2022 Oladipo Cole Genitourinary Cancers
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
➤ PubMed
Michael Slade Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer ➤ PubMed
May 19, 2022 Andrew Young Gyn Onc Malignancies
Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer
➤ PubMed
Bindiya Patel Inherent Mosaicism and Extensive Mutation of Human Placentas ➤ PubMed
May 26, 2022 Jesse Zaretsky Central/Peripheral Nervous System Cancer
CAR T Cell Killing Requires the IFNγR Pathway in Solid but Not Liquid Tumours
➤ PubMed
Jun 14, 2022 Joshua Siner Classical Hematology
Mitapivat Versus Placebo for Pyruvate Kinase Deficiency
➤ PubMed
Rigoberto De Jesus Pizarro Lupus Anticoagulant Test Persistence Over Time and Its Associations With Future Thrombotic Events ➤ PubMed
Jun 22, 2022 Dilan Patel Myeloma/Leukemia
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
➤ PubMed
Fahrettin Covut Triplet Therapy, Transplantation, and Maintenance Until Progression in Myeloma ➤ PubMed
Jun 23, 2022 Nicole Foley Thrombosis/Bleeding Disorders
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
➤ PubMed
Stefan Tarnawsky Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data ➤ PubMed
Jun 28, 2022 David Russler-Germain Lymphoma
Ibrutinib Plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
➤ PubMed
Zachary Crees Axicabtagene Ciloleucel as First-Line Therapy in High-Risk Large B-Cell Lymphoma: The Phase 2 ZUMA-12 Trial ➤ PubMed